Estradiol transdermal system versus oral estrogenonly hormone therapy on the impact of venous thromboembolism

0
691

The aim of the current study was to quantify the magnitude of risk reduction for venous thromboembolism events associated with an estradiol transdermal system relative to oral estrogen-only hormone therapy agents. A claims analysis was conducted using the Thomson Reuters MarketScan database from January 2002 to October 2009. Participants included women aged 35 years or older who were newly using an estradiol transdermal system or an oral estrogen-only hormone therapy with two or more dispensings. Venous thromboembolism was defined as one or more diagnosis codes for deep vein thrombosis or pulmonary embolism. Cohorts of estradiol transdermal system and oral estrogen-only hormone therapy were matched. Among the matched estradiol transdermal system and oral estrogen-only hormone therapy users (27 018 women in each group), the mean age of the cohorts was 48.9 years; in each cohort, 6044 (22.4%) and 1788 (6.6%) participants had a hysterectomy and an oophorectomy at baseline, respectively. The incidence of venous thromboembolism was significantly lower in participants receiving an estradiol transdermal system compared to estrogen-only hormone users (unadjusted incidence rate ratio: 0.72; 95% CI: 0.57-0.91; P = 0.006) and this effect remained after adjustment for confounding factors. Menopause. 2011 Oct;18(10):1052-9. PMID: 21775912.

LEAVE A REPLY

Please enter your comment!
Please enter your name here